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Abstract
Pulmonary diseases are commonly encountered by primary care physicians in the outpatient setting. Despite their prevalence, many physicians may be unfamiliar with the diagnosis and appropriate management of these disorders. The evidence-based pearls in this article will help primary care physicians navigate important topics in pulmonary medicine and guide their decision to refer their patients to a pulmonary specialist. 3 The same recommendations apply even if multiple solid pulmonary nodules smaller than 6 mm are present. Note that these new guidelines are less intensive than prior guidelines, as the threshold for follow-up imaging has increased (from 4 mm previously), thereby eliminating many unnecessary CT scans. This guideline change is based on supporting evidence from screening trials that indicate that the risk of cancer in solid nodules smaller than 6 mm is less than 1%, even in patients considered at high risk. 4 A CT scan at 12 months can be considered optional for nodules smaller than 6 mm in high-risk patients and may be considered more seriously in those with suspicious nodule morphology (eg, spiculated margins) or upper lobe location. For solid nodules that are 6 to 8 mm, follow-up CT is recommended in all cases; the timing and frequency is dependent on the size, type, and number of nodules. For solid nodules larger than 8 mm, consider 3-month follow-up imaging, work-up with combined positron emission tomography and CT, tissue sampling, or a combination of these methods; any of these options may be appropriate, and a pulmonary specialist can assist with decision making. Importantly, these specific guidelines pertain to pulmonary nodules found incidentally on CT; separate recommendations (Lung-RADS [Lung Imaging Reporting and Data System]) proposed by the American College of Radiology exist for nodules found on annual low-dose CT screening for lung cancer. 5 Lastly, updated recommendations for subsolid and ground-glass nodules are also provided by the 2017 Fleischner Society guidelines.
In Patients With Acute Chronic Obstructive Pulmonary Disease Exacerbation, a 5-Day Course of Prednisone Is as Effective as a 14-Day Course
Most chronic obstructive pulmonary disease (COPD) exacerbations (up to 80%) are managed in the outpatient setting. 6 The use of systemic glucocorticoids in COPD exacerbations shortens recovery time, improves lung function and oxygenation, and decreases the risk of early relapse. 7 However, glucocorticoids are also well known to have many adverse effects, and long-term use is an independent risk factor for increased mortality in COPD. 8 The optimal duration of systemic glucocorticoid treatment for COPD exacerbation was not well defined until the results of the REDUCE (Reduction in the Use of Corticosteroids in Exacerbated COPD) trial 9 were published in 2013. Prior guidelines had generally recommended a 7-to 14-day course of systemic glucocorticoid therapy for COPD exacerbations. The REDUCE trial found that in patients presenting to the emergency department with acute COPD exacerbations, a 5-day treatment course with prednisone, 40 mg daily, was noninferior to a 14-day treatment course with respect to re-exacerbation rates. These results can be extrapolated to the outpatient setting because the benefit of oral glucocorticoids in the outpatient management of COPD exacerbations has been well established. 10 
Pulmonary Rehabilitation Is a Standard of Care for All Patients With Symptomatic Chronic Lung Disease
Every patient with chronic lung disease who is symptomatic or has a decreased quality of life should be strongly considered for pulmonary rehabilitation. The American College of Physicians, ACCP, and American Thoracic Society recommend that clinicians prescribe pulmonary rehabilitation for symptomatic patients with a forced expiratory volume in the first second of expiration (FEV 1 ) of less than 50% predicted and should consider it for symptomatic patients with an FEV 1 of greater than 50% predicted. 11 There is now a wealth of evidence that pulmonary rehabilitation yields reduction in dyspnea and hospital readmissions, increase in exercise performance, and improvement in health-related quality of life. 12 These results hold true regardless of the type of chronic respiratory disease and are not limited to patients with COPD. Optimal benefits are achieved through programs lasting 6 to 12 weeks. Pulmonary rehabilitation uses a multidisciplinary approach individualized to each patient. It has no direct effect on airflow limitations or diffusion capacities; rather, it reduces the respiratory load at a given exercise load by improving peripheral muscle dysfunction, ventilation, dynamic hyperinflation, and decreasing lactate production. Despite these benefits, pulmonary rehabilitation remains significantly underutilized, with an estimated 2% of the COPD population being referred. 13 Referral rates are low because practitioners often view pulmonary rehabilitation as a last resort to treat patients with severe respiratory disease. Additionally, patient-related barriers exist. Access to pulmonary rehabilitation, which is generally center-based, may be particularly challenging in rural settings, and transportation remains a potential barrier in any setting.
If access or transportation is an issue, consideration can be given to home-based pulmonary rehabilitation programs. A recent study by Holland et al 14 found that a simple home-based pulmonary rehabilitation program using minimal resources and less direct supervision produced equivalent clinical outcomes (exercise capacity and health-related quality of life) compared with a conventional center-based program in patients with COPD. In this study, the main features of the home-based treatment plan were 30 minutes of daily aerobic training using a modality accessible to the patient (usually walking), and resistance training accessible in the home environment (eg, sit-to-stand from a chair, step-ups on an internal or external step, water bottles for upper limb weights). Furthermore, program adherence and completion were significantly higher in the homebased treatment group compared with those in the center-based treatment group.
Annual Low-Dose CT Screening for Lung Cancer in High-Risk Individuals Is Recommended by Most Expert Groups
The National Lung Screening Trial 15 found that annual low-dose CT screening in a high-risk population (eligible participants were between 55 and 74 years of age with at least 30 pack-years of cigarette smoking who were current smokers or had quit within the previous 15 years) reduced mortality by 20% compared with screening by chest radiography. These results led most major expert groups to update their recommendations. In 2013, the US Preventive Services Task Force (USPSTF) updated its prior long-standing recommendation that there was insufficient evidence to recommend for or against lung cancer screening in asymptomatic patients; the USPSTF now recommends annual screening with low-dose CT in adults aged 55 to 80 years who have a 30-pack-year smoking history and currently smoke or have quit within the past 15 years. 16 Furthermore, the American Association for Thoracic Surgery recommends screening a larger population by broadening both the age and risk categories; in addition to guidelines similar to those from the USPSTF, they recommend annual screening starting at age 50 to 79 years in patients who have a 20-pack-year smoking history and additional comorbid conditions that produce a cumulative risk for cancer of at least 5% over the next 5 years (eg, COPD with FEV 1 <70%, history of lung cancer, family history of lung cancer). 17 These extended criteria are similar to those included by the National Comprehensive Cancer Network. 18 Patients should be counseled regarding the high false-positive rate of such screening practices and the subsequent need for further evaluation (eg, additional or serial imaging, needle biopsy, bronchoscopy, thoracoscopy); of the total number of low-dose CT screening tests performed in the National Lung Screening Trial, 23% had false-positive results compared with 6.5% of those that underwent radiographic screening. 15 The cost-effectiveness for these screening recommendations is undergoing further analysis. As of 2015, Medicare covers annual low-dose helical CT screening for asymptomatic patients aged 55 to 77 years with at least a 30-pack-year smoking history and who are either a current smoker or quit smoking within the past 15 years. 19 Screening should be discontinued once the patient has not smoked for 15 years. 16 
Nitrofurantoin Can Cause Severe Pulmonary Injury and Is Not Recommended for Long-term Suppressive Treatment of Urinary Tract Infections
Nitrofurantoin is a commonly prescribed medication in the primary care setting. It is mainly used for treatment of acute cystitis and long-term prevention of recurrent urinary tract infections. However, it is not well known that this drug can cause both an acute and chronic form of pulmonary toxicity. The 2015 American Geriatrics Society Beers criteria recommends against the use of nitrofurantoin for longer-term suppression of urinary tract infections because it is considered inappropriate due to pulmonary toxicity concerns. 20 The acute form of pulmonary toxicity occurs 1 to 2 weeks after short courses of nitrofurantoin therapy. Symptoms can include abrupt onset of fever (82%), dyspnea (60%), cough (43%), and rash (20%). 21 The chronic form of pulmonary toxicity usually develops after several months to years of low-dose treatment and typically presents as an insidious onset of symptoms; dyspnea and cough are the most commonly reported symptoms, while fever is uncommon. 22 Abnormalities on chest radiography, notably parenchymal changes, are seen in most patients with both the acute and chronic forms. Discontinuation of nitrofurantoin generally results in resolution of symptoms in both the acute and chronic forms of pulmonary toxicity. Physicians should be vigilant regarding this disease presentation because prognosis is excellent if it is recognized early and nitrofurantoin exposure is stopped. If chronic pulmonary toxicity from nitrofurantoin is suspected, a pulmonary specialist should be consulted to distinguish it from other chronic pulmonary processes and to determine if further evaluation is warranted.
Antibiotics Improve Outcomes in Patients With COPD Exacerbations but Not in Patients With Acute Bronchitis
Viral respiratory infections are known to be the most common cause of COPD exacerbations. Consequently, the use of antibiotics in the management of COPD exacerbations has been a controversial topic in the past. There is now increasing evidence supporting the use of antibiotics in the treatment of COPD exacerbations. Ram et al 23 conducted a systematic review of randomized controlled trials and found that antibiotics reduced the risk of short-term mortality by 77% and treatment failure by 53%. Additionally, the 2018 report of the Global Initiative for Chronic Obstructive Lung Disease 24 continues to recommend the use of antibiotics in patients who exhibit the following 3 cardinal symptoms: increased dyspnea, sputum volume, and sputum purulence. Conversely, the empiric use of antibiotics is not recommended in the treatment of uncomplicated acute bronchitis in patients without COPD exacerbation. Acute bronchitis is one of the most common conditions for which patients seek medical care, and it is estimated that 50% to 80% of patients with acute bronchitis who seek care are prescribed antibiotics. 25 However, studies have found that antibiotics do not improve symptom scores or cure rates when compared with placebo in patients with a diagnosis of acute bronchitis who have a history of COPD. 26 Furthermore, antibiotic overuse continues to contribute to increasing antibiotic resistance, drug adverse effects, and Clostridium difficile infections. Use of antibiotics in acute bronchitis should be limited to cases in which a specific pathogen is suspected or in patients at increased risk for complications.
It Is Never Too Late to Quit Smoking
Each year, approximately two-thirds of all smokers in the United States make an attempt to quit. 27 The landmark Lung Health Study was a randomized clinical trial of smoking cessation that validated its significant benefits. 28 In this study, the development of clinically significant airway obstruction was largely prevented in smokers who quit compared with those who did not. Differences in lung function (FEV 1 ) widened progressively between those who quit smoking and those who did notdsustained quitters had an overall 5-year decline in FEV 1 of 72 mL, while continued smokers' in FEV 1 declined by 301 mL. Furthermore, smoking cessation was associated with significant reductions in death, coronary vascular disease, and coronary artery disease; continued smoking was associated with 50% to 70% higher hazards in these end points.
If adequate resources are dedicated to smoking cessation, long-term quit success rates of up to 25% to 35% can be achieved. 29 A combination of pharmacotherapy and behavioral interventions should be offered because this approach is superior to either intervention alone. 30 First-line pharmacotherapies for smoking cessation are nicotine replacement therapy, varenicline, and bupropion; Cahill et al 31 conducted network meta-analyses that revealed that all 3 pharmacotherapies were superior to placebo for odds of quitting, with the following odds ratios (95% credibility intervals): varenicline, 2.88; bupropion, 1.84; and nicotine replacement therapy, 1.82. Likewise, behavioral counseling is effective in increasing smoking cessation rates, including both individual and group therapy. In fact, even brief periods of counseling (3 minutes or less) have been reported to double the cessation rate compared with simple advising to stop smoking. 32 If office-based support is not available or if additional support is desired, referral to free telephone quit lines (1-800-QUIT-NOW in the United States) is a good option that typically provides proactive smoking cessation counseling over several calls. 27 Physicians should also recognize that relapse after smoking cessation is very common, and continued assessment is essential even after patients report cessation. All smokers should be advised to quit smoking and be offered smoking cessation counseling.
Normal Findings on Spirometry Do Not Exclude the Diagnosis of Asthma. A Negative Bronchoprovocation Test Result Does Reliably Exclude the Diagnosis of Asthma
The definitive diagnosis of asthma requires documentation of variable expiratory airflow obstruction in addition to respiratory symptoms consistent with asthma, including cough, wheezing, and dyspnea. 33 However, patients with asthma who do not have current symptoms often have normal spirometric results. Therefore, normal spirometric findings do not rule out the diagnosis of asthma. When patients are symptomatic, airflow limitation is indicated by a decreased FEV 1 and FEV 1 to forced vital capacity (FVC) ratio. Further diagnostic value is gained with the inclusion of bronchoprovocation testing such as a methacholine challenge test because patients with asthma are hyperresponsive to such stimuli. 34 Importantly, negative results on bronchoprovocation testing (no substantial decline in FEV 1 at the highest dose of methacholine administration) reliably exclude the diagnosis of asthma. Additional information is obtained by assessing the degree of bronchodilator response, which is performed after baseline spirometry without bronchoprovocation. A positive bronchodilator response (increase in FEV 1 and/or FVC by 12% or more and by at least 200 mL) can support the diagnosis of asthma because airflow limitation from asthma is expected to exhibit some degree of reversibility following short-term treatment with a bronchodilator. However, a positive bronchodilator response is not sufficient to definitively establish the diagnosis of asthma because this response can be seen with other pulmonary conditions such as COPD, bronchiectasis, and bronchiolitis.
Recognize the Classic Signs and Symptoms of COPD. Use Spirometry to Establish a Diagnosis of COPD in Symptomatic Patients
Chronic obstructive pulmonary disease is the third leading cause of death in the United States. 35 Once a patient experiences a COPD exacerbation, they are more likely to experience future exacerbations, decline in lung function, reduced exercise tolerance, poorer quality of life, and an increased risk of death. The following are key indicators for considering a diagnosis of COPD: persistent and progressive dyspnea, chronic cough, chronic sputum production, history of risk factors (eg, exposure to tobacco smoke, occupational dusts and chemicals, pollution), and family history of COPD. 24 Concomitant chronic diseases such as cardiovascular disease and lung cancer should also be actively sought and treated appropriately because they frequently occur in patients with COPD and can affect morbidity and mortality independently. Spirometry is required to establish a diagnosis of COPD; the presence of a postbronchodilator FEV 1 :FVC ratio of less than 0.70 confirms the presence of airflow limitation and thus the diagnosis of COPD in patients with appropriate symptoms and substantial exposures.
In 2016, the USPSTF reiterated its recommendation against screening asymptomatic adults for COPD, citing a systematic literature review by Guirguis-Blake et al, 36 which found no direct evidence to determine the benefits and harms of screening asymptomatic adults for COPD using questionnaires or screening spirometry. In patients with respiratory symptoms, however, spirometry should be obtained to diagnose airflow obstructiondthis is a strong recommendation included in the most recent guideline update from the American College of Physicians, ACCP, and American Thoracic Society. 11 Likewise, the 2018 Global Initiative for Chronic Obstructive Lung Disease guidelines recommend that COPD should be considered and spirometry should be performed if any of the aforementioned key indicators are present in an individual over age 40 years. 24 Although spirometry is a simple procedure that can be performed in the outpatient setting, it remains underutilized by primary care physicians.
Air Travel Can Be Safe for Patients With
Severe Pulmonary Disease, but These Patients Should Be Properly Evaluated Beforehand Practitioners are often approached by patients regarding the risks of air travel. Patients with underlying pulmonary disease are at increased risk for medical emergencies because they have limited ability to compensate for the effects of decreased cabin pressure. 37 National aviation regulations state that airplanes must maintain a partial pressure of oxygen that corresponds to a maximum altitude of 8000 feet, which is equivalent to breathing approximately 15% oxygen (compared to 21% at sea level). 38 Unlike healthy patients, those with pulmonary disease may have limited reserve to compensate for the lower partial pressure of oxygen.
In 2011, the British Thoracic Society (BTS) published updated guidelines based on expert consensus from literature reviews for the evaluation of patients with pulmonary disease before air travel. 39 They reviewed data from several studies and determined that variables such as resting sea level oxygen saturation and FEV 1 did not appear to predict hypoxemia or complications accurately during or after air travel in patients with respiratory disease. 40, 41 Importantly, this finding led the BTS to update their guidelines to state that there is no reliable threshold in these variables to determine the safety of air travel and need for in-flight oxygen (prior guidelines had recommended using these variables). Nevertheless, the updated guidelines emphasize the need for practical recommendations. In general, patients should be stable and recovered from any recent exacerbation before travel. Additionally, physicians should consider the patient's previous flight experience and the expected flight duration. It is recommended that those with the following conditions be assessed with history and examination as a minimum: severe COPD (FEV 1 <30% predicted) or asthma, severe restrictive disease (vital capacity <1 L), bullous lung disease, cystic fibrosis, recent pneumothorax, comorbidity with conditions worsened by hypoxemia (eg, cardiac disease), risk of or previous venous thromboembolism, previous air travel intolerance with severe respiratory symptoms, preexisting requirement for oxygen or ventilator support, and within 6 weeks of hospital discharge for an acute respiratory illness. 39 Furthermore, patients with any of these risk factors can be considered for a hypoxia altitude simulation test (HAST) referral, which is a useful test for evaluation of patients with underlying lung disease before air travel. This relatively simple test involves the administration of a hypoxic gas mixture that replicates the in-flight partial pressure of inspired oxygen at 8000 feet: in-flight oxygen is recommended if the HAST results in a PaO 2 of less than 50 mm Hg or peripheral capillary oxygen saturation of less than 85%. Although the HAST is relatively cheap and covered by Medicare, not everyone will have access to this procedure. In that case, the decision for air travel should take into account the physician's practical approach and assessment, and ultimately it should be made clear that the patient takes responsibility for deciding to fly. Finally, the HAST can be used to assess for increased oxygen requirement among patients who already require long-term supplemental oxygen; if an HAST is not available, an alternative is to increase the oxygen flow 1 to 2 L/min over the patient's baseline requirement while in flight. 39 The BTS guidelines list the following as contraindications to commercial air travel: infectious tuberculosis, ongoing pneumothorax with persistent air leak, hemoptysis, and baseline oxygen requirement at sea level exceeding 4 L/min. If oxygen is required, it is usually supplied by the airline and must be scheduled beforehand. Most airlines require notification of the need for in-flight oxygen at least 48 hours before the trip. Therefore, screening and assessment of patients at risk should be planned appropriately in advance.
CONCLUSION
Pulmonary diseases are commonly encountered by physicians in the primary care setting. Early identification and appropriate management are effective in reducing the substantial morbidity and mortality often associated with pulmonary diseases. 
